SRR934981
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.690
- G2M_CHECKPOINT+0.650
- MYC_TARGETS_V1+0.614
- MYC_TARGETS_V2+0.587
- UNFOLDED_PROTEIN_RESPONSE+0.487
- TGF_BETA_SIGNALING+0.483
- TNFA_SIGNALING_VIA_NFKB+0.482
- MTORC1_SIGNALING+0.421
- MITOTIC_SPINDLE+0.417
- IL6_JAK_STAT3_SIGNALING+0.413
Top 10 suppressed
- KRAS_SIGNALING_DN-0.389
- MYOGENESIS-0.241
- BILE_ACID_METABOLISM-0.192
- APICAL_SURFACE-0.121
- SPERMATOGENESIS-0.113
- XENOBIOTIC_METABOLISM-0.044
- APICAL_JUNCTION-0.024
- PANCREAS_BETA_CELLS-0.012
- CHOLESTEROL_HOMEOSTASIS-0.005
- COAGULATION+0.039
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.964 |
| 2 | EB8F7B74-694A-4F9F-9C0B-F04006033CA4 | — | — | 0.949 |
| 3 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.942 |
| 4 | 6B8CAF74-45C6-4C20-8126-A99F73346198 | — | — | 0.941 |
| 5 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.940 |
| 6 | B27956E8-3374-4720-9F80-7CE6FE7C7690 | — | — | 0.940 |
| 7 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.939 |
| 8 | D5191F3D-028E-401C-927E-483F6884BE39 | — | — | 0.938 |
| 9 | SRR934835 | — | — | 0.938 |
| 10 | 6AF1465C-7A6C-4AAF-AFF2-3065EA5B7D0B | — | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.690 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.650 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.614 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.587 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.487 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.483 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.482 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.421 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.417 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.413 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.383 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| APOPTOSIS | 0.372 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.336 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.336 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.334 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.331 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.325 | Remibrutinib | — uncovered |